12:00 AM
 | 
Jun 13, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CC-115: Phase I data

Top-line data from 82 evaluable patients with relapsed or refractory advanced solid tumors and hematological malignancies in a 2-part, open-label, international Phase Ia/Ib trial showed that oral CC-115 led to 1 complete response in a patient with endometrial cancer, 1 partial response in a patient with melanoma and 4 partial responses (3 with lymphocytosis)...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >